A shared molecular weakness in glioblastoma tumor cells may offer a new treatment target
Researchers at the Icahn School of Medicine at Mount Sinai have identified a shared molecular trait in glioblastoma, an aggressive brain cancer in adults. It resembles one used by immature cells during brain development and may reveal a target for future treatments.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a shared molecular trait in glioblastoma cells, an aggressive brain cancer. This trait resembles that of immature glial intermediate progenitor cells, which play a role in brain development. The study, published in the journal Neuron, identified a protein called POU3F3 as a key regulator of this trait.
In experiments with patient-derived tumor cells, reducing POU3F3 activity made the cells less aggressive, suggesting a potential target for future treatments. Glioblastoma is known for its heterogeneity, with many different types of cancer cells within a single tumor. Despite this diversity, the researchers found that many glioblastoma cells share a gene activity pattern resembling that of gIPCs.
This shared developmental program, regulated by POU3F3, may provide a new target for developing therapies against this difficult-to-treat cancer.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.